| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| P2093 | author name string | David J Liewehr | |
| Seth M Steinberg | |||
| Donald E White | |||
| James C Yang | |||
| Douglas J Schwartzentruber | |||
| Lisa M Guirguis | |||
| P2860 | cites work | Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer | Q33503368 |
| Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma | Q36119828 | ||
| Brain metastasis after immunotherapy in patients with metastatic melanoma or renal cell cancer: is craniotomy indicated? | Q45077693 | ||
| Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b | Q56891369 | ||
| Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer | Q70649453 | ||
| Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 | Q72052802 | ||
| Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 | Q72275233 | ||
| Renal dysfunction associated with the administration of high-dose interleukin-2 in 199 consecutive patients with metastatic melanoma or renal carcinoma | Q72880149 | ||
| Reduction of brain metastasis following immunotherapy with interleukin-2 for stage IV renal cell cancer | Q73317855 | ||
| Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response | Q77317862 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 82-87 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Journal of Immunotherapy | Q15763946 |
| P1476 | title | Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases | |
| P478 | volume | 25 |
| Q57172250 | Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies |
| Q55206910 | An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. |
| Q43576243 | Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival |
| Q39331752 | Challenges in the delivery of therapies to melanoma brain metastases |
| Q38548397 | Clinical Management of Multiple Melanoma Brain Metastases: A Systematic Review. |
| Q90436833 | Complications associated with immunotherapy for brain metastases |
| Q38187117 | Dabrafenib for treatment of BRAF-mutant melanoma |
| Q26745933 | Dabrafenib: a new opportunity for the treatment of BRAF V600-positive melanoma |
| Q30457624 | Dystonia in a patient with melanoma metastatic to the brain treated with high-dose interleukin-2, radiation therapy, and levetiracetam |
| Q36618229 | Efficacy of systemic adoptive transfer immunotherapy targeting NY-ESO-1 for glioblastoma |
| Q38598521 | Evolving treatment options for melanoma brain metastases |
| Q84169355 | Extending the reach of BRAF-targeted cancer therapy |
| Q48258912 | Gamma knife radiosurgery in the management of malignant melanoma brain metastases |
| Q59400683 | High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014 |
| Q36883292 | High-Dose Interleukin-2 (HD IL-2) Therapy Should Be Considered for Treatment of Patients with Melanoma Brain Metastases |
| Q47653459 | Improved survival of patients with melanoma brain metastases in the era of targeted BRAF and immune checkpoint therapies. |
| Q26801403 | In Vitro T-Cell Generation From Adult, Embryonic, and Induced Pluripotent Stem Cells: Many Roads to One Destination |
| Q41274844 | Ipilimumab in a Phase II trial of melanoma patients with brain metastases |
| Q64971747 | Management of metastatic cutaneous melanoma: updates in clinical practice. |
| Q30251581 | Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy |
| Q44733547 | Measurement of cytotoxic activity in experimental cancer. |
| Q26995622 | Melanoma brain metastases: an unmet challenge in the era of active therapy |
| Q37159517 | Melanoma-induced brain metastases |
| Q33367980 | Multidisciplinary treatment of brain metastases derived from clear cell renal cancer incorporating stereotactic radiosurgery |
| Q38146716 | Novel treatments for melanoma brain metastases |
| Q48166330 | Predictors of survival, neurologic death, local failure, and distant failure after gamma knife radiosurgery for melanoma brain metastases |
| Q39177404 | Sequencing brain metastases and opportunities for targeted therapies |
| Q37414808 | Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma |
| Q42933679 | Successful treatment of melanoma brain metastases with adoptive cell therapy. |
| Q48961952 | Supratentorial gross-totally resected non-anaplastic ependymoma: population based patterns of care and outcomes analysis. |
| Q34954990 | Surgical management of melanoma brain metastases in patients treated with immunotherapy. |
| Q26750891 | Systemic Immunotherapy for the Treatment of Brain Metastases |
| Q38646117 | Treatment of Melanoma CNS Metastases |
| Q36284501 | Treatment options for brain metastases from melanoma |
| Q36023879 | Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting |
| Q56892924 | Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy |
Search more.